Literature DB >> 22235917

Poly(galactaramidoamine) is an efficient cationic polymeric non-viral vector with low cytotoxicity for transfecting human embryonic kidney (HEK293) and murine macrophage (RAW264.7) cells.

Amaraporn Wongrakpanich1, Vijaya B Joshi, Aliasger K Salem.   

Abstract

Poly(galactaramidoamine) (PGAA) is a cationic co-polymer of dimethyl-meso-galactarate and pentaethylenehexamine. PGAA electrostatically complexes with plasmid DNA (pDNA) to form nano-sized particles. In this study, we show that PGAA-pDNA polyplexes generate high transfection efficiencies in human embryonic kidney (HEK293) and murine macrophage-like (RAW264.7) cell lines. PGAA-pDNA mediated transfection is a function of the amine:phosphate (N/P) ratio at which the polyplexes are prepared. The maximum expression of luciferase was obtained using polyplexes prepared at an N/P ratio of 40. Polyplexes prepared at increasing N/P ratios did not significantly increase in size but did result in decreasing luciferase expression. Cellular toxicity increased as the N/P ratios at which the polyplexes were prepared increased.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22235917      PMCID: PMC3638068          DOI: 10.3109/10837450.2011.649856

Source DB:  PubMed          Journal:  Pharm Dev Technol        ISSN: 1083-7450            Impact factor:   3.133


  12 in total

1.  Poly(glycoamidoamine) vehicles promote pDNA uptake through multiple routes and efficient gene expression via caveolae-mediated endocytosis.

Authors:  Patrick M McLendon; Katye M Fichter; Theresa M Reineke
Journal:  Mol Pharm       Date:  2010-06-07       Impact factor: 4.939

Review 2.  Poly(glycoamidoamine)s: a broad class of carbohydrate-containing polycations for nucleic acid delivery.

Authors:  Nilesh P Ingle; Brett Malone; Theresa M Reineke
Journal:  Trends Biotechnol       Date:  2011-06-24       Impact factor: 19.536

3.  Optimized dextran-polyethylenimine conjugates are efficient non-viral vectors with reduced cytotoxicity when used in serum containing environments.

Authors:  Dahai Jiang; Aliasger K Salem
Journal:  Int J Pharm       Date:  2011-10-21       Impact factor: 5.875

4.  Synthesis and characterization of mannosylated pegylated polyethylenimine as a carrier for siRNA.

Authors:  Najung Kim; Dahai Jiang; Ashley M Jacobi; Kim A Lennox; Scott D Rose; Mark A Behlke; Aliasger K Salem
Journal:  Int J Pharm       Date:  2011-08-12       Impact factor: 5.875

5.  Interaction of poly(glycoamidoamine) DNA delivery vehicles with cell-surface glycosaminoglycans leads to polyplex internalization in a manner not solely dependent on charge.

Authors:  Patrick M McLendon; Daniel J Buckwalter; Erica M Davis; Theresa M Reineke
Journal:  Mol Pharm       Date:  2010-08-16       Impact factor: 4.939

6.  Hydroxyl stereochemistry and amine number within poly(glycoamidoamine)s affect intracellular DNA delivery.

Authors:  Yemin Liu; Theresa M Reineke
Journal:  J Am Chem Soc       Date:  2005-03-09       Impact factor: 15.419

7.  Degradation of poly(glycoamidoamine) DNA delivery vehicles: polyamide hydrolysis at physiological conditions promotes DNA release.

Authors:  Yemin Liu; Theresa M Reineke
Journal:  Biomacromolecules       Date:  2010-02-08       Impact factor: 6.988

8.  New poly(d-glucaramidoamine)s induce DNA nanoparticle formation and efficient gene delivery into mammalian cells.

Authors:  Yemin Liu; Laura Wenning; Matthew Lynch; Theresa M Reineke
Journal:  J Am Chem Soc       Date:  2004-06-23       Impact factor: 15.419

9.  Characterization of the transgene expression generated by branched and linear polyethylenimine-plasmid DNA nanoparticles in vitro and after intraperitoneal injection in vivo.

Authors:  Janjira Intra; Aliasger K Salem
Journal:  J Control Release       Date:  2008-04-24       Impact factor: 9.776

10.  Rational design, fabrication, characterization and in vitro testing of biodegradable microparticles that generate targeted and sustained transgene expression in HepG2 liver cells.

Authors:  Janjira Intra; Aliasger K Salem
Journal:  J Drug Target       Date:  2010-08-03       Impact factor: 5.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.